about
Tryptase haplotype in mastocytosis: relationship to disease variant and diagnostic utility of total tryptase levelsMolecular diagnosis of mast cell disorders: a paper from the 2005 William Beaumont Hospital Symposium on Molecular PathologyBiomarkers of the involvement of mast cells, basophils and eosinophils in asthma and allergic diseasesKIT mutation analysis in mast cell neoplasms: recommendations of the European Competence Network on MastocytosisMolecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome.Advanced systemic mastocytosis: from molecular and genetic progress to clinical practiceEfficacy and Safety of Midostaurin in Advanced Systemic MastocytosisCurrent options in the treatment of mast cell mediator-related symptoms in mastocytosis.Anaphylaxis and mast cell disease: what is the risk?Demonstration that mast cells, T cells, and B cells bearing the activating kit mutation D816V occur in clusters within the marrow of patients with mastocytosis.A clinicopathologic study of 24 cases of systemic mastocytosis involving the gastrointestinal tract and assessment of mucosal mast cell density in irritable bowel syndrome and asymptomatic patientsMast cell activation syndrome: Proposed diagnostic criteria.Refined diagnostic criteria and classification of mast cell leukemia (MCL) and myelomastocytic leukemia (MML): a consensus proposalMastocytosis: molecular mechanisms and clinical disease heterogeneity.Surrogate markers of disease in mastocytosis.Hematopoietic stem-cell transplantation for advanced systemic mastocytosis.Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria.Mast cell proliferative disorders: current view on variants recognized by the World Health Organization.Definitions, criteria and global classification of mast cell disorders with special reference to mast cell activation syndromes: a consensus proposalOn the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts.Demonstration of an aberrant mast-cell population with clonal markers in a subset of patients with "idiopathic" anaphylaxisThe serum tryptase test: an emerging robust biomarker in clinical hematology.Clonality and molecular pathogenesis of mastocytosis.Pathogenesis, clinical features, and treatment advances in mastocytosis.Urticaria pigmentosa and mastocytosis: the role of immunophenotyping in diagnosis and determining response to treatment.International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT) & European Competence Network on Mastocytosis (ECNM) consensus response criteria in advanced systemic mastocytosis.Mastocytosis: advances in diagnosis and treatment.Pharmacological targeting of the KIT growth factor receptor: a therapeutic consideration for mast cell disorders.Mastocytosis and allergy.Tyrosine kinase inhibitors in the treatment of systemic mastocytosis.Mast cells and eosinophils in mastocytosis, chronic eosinophilic leukemia, and non-clonal disorders.Mast cell sarcoma: a rare and potentially under-recognized diagnostic entity with specific therapeutic implications.Mast cell activation syndromes.Mastocytosis: update on pharmacotherapy and future directions.Primary mast cell disorders in children.Diagnostic criteria and classification of mastocytosis in 2014.Treatment strategies in mastocytosis.Mast cell activation disorders.Current treatment options in patients with mastocytosis: status in 2015 and future perspectives.Mast cell activation syndromes presenting as anaphylaxis.
P50
Q24679397-9B826617-03EC-4272-9174-93A73501BABAQ24685914-1C837766-634E-4D36-A67C-1EDF4C02DCBCQ26767423-DA5C556D-2869-4983-BEDC-2B6FFB6FD6B1Q26830207-0701CBD4-77AF-4452-9F67-5DDC4B45C800Q27824799-211B97FD-71F5-4311-B49B-52C2CCCCE9FDQ28068458-D1778227-53B1-4F63-8971-865CC370866FQ28314922-0642580F-339D-44F7-8781-AE09796EEF32Q33153706-67314403-BCDB-45B5-BDE1-BF0A1915676EQ33158677-698057AB-1EBB-47E7-9A7B-90C9B5F4DFB7Q33208353-9F1C26C8-76D1-44C8-84B7-8F810FB5206BQ33863692-1F070E8A-077F-445D-B5DB-6BE4BE0D0E2EQ34024510-3466ED2C-358B-420E-86FC-6E2FCDFF4BCBQ34137971-BC111F00-4E7A-4918-ACAA-723A111A89DBQ34264319-AC55F0E4-8C37-46D0-AD0C-DA2397CD2826Q34580191-1FB7C048-B094-476C-80A9-24D171192AB6Q34664111-4DC9C713-4DEA-4C08-BC71-DB94D9F09550Q35101794-F0885B7D-C97B-4584-8E8F-0D03E140B69DQ35560203-091416D5-68F4-4153-A699-6C2100AC58ADQ35574171-FBB18F0C-FA5B-4D6A-85B9-850B0CCD7A64Q35854970-3B18FB52-6150-4C82-8F37-EE0D6C641877Q36007641-AF4B7A4A-C272-458F-AE36-E5265EEF6EFBQ36154674-9A6D8F16-BD84-4AB8-A9CC-7BFD1110019BQ36182758-DCB77E0C-8EF4-4A58-AD9E-90612EEF2573Q36509822-F764060E-DD26-4E30-941F-35BEA0887913Q36527862-A6636BDD-B743-424D-9925-51BF763F205BQ36730397-996A1BEE-6F2F-4AAF-923C-6ADDC84AF477Q36839953-2570E9EC-8380-4D30-B3CA-02CB1715F60CQ36842503-3ABA7DC6-AEE5-4890-A5F1-73BD0994FB45Q36943497-1D88E228-EBCD-4E72-B454-4C31C0FAE091Q37884959-B26965ED-FA75-4C77-912D-039F0326383CQ37997162-EF6AF403-2843-495D-833B-1A37D699DF06Q38063759-A6D3C98F-76B3-4B54-8D77-2CD94192DB37Q38117449-E03706CC-C99E-4F3A-9334-C6C92D8145D5Q38138597-3E8FD1D1-ADA8-4399-AAC7-926518375D67Q38154827-B51FEADA-B044-48B0-AFE3-4076A0632AD6Q38205498-171DC715-9A26-4B33-902A-C4B3A1AD1F13Q38205510-808EC698-BABA-41D7-B849-C1463661277FQ38210378-23DD6E28-E4CF-4C4A-B757-2ACBD4A2AE6AQ38370943-7F9F467F-FAFB-4403-AA60-CABCBF633309Q38405309-BA268433-8573-4239-9F2E-A61BD35F0821
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
ricercatore
@it
հետազոտող
@hy
name
Cem Akin
@ast
Cem Akin
@en
Cem Akin
@es
Cem Akin
@nl
Cem Akin
@sl
type
label
Cem Akin
@ast
Cem Akin
@en
Cem Akin
@es
Cem Akin
@nl
Cem Akin
@sl
prefLabel
Cem Akin
@ast
Cem Akin
@en
Cem Akin
@es
Cem Akin
@nl
Cem Akin
@sl
P108
P214
P106
P21
P214
P31
P496
0000-0001-6301-4520
P734
P735
P7859
lccn-no2011069358